Pompilio, G., Morabito, A., Cortinovis, D. L. and Integlia, D. (2022) “Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations”, Global and Regional Health Technology Assessment, 9(1), pp. 22–29. doi: 10.33393/grhta.2022.2351.